Literature DB >> 20725015

Biotechnology: Crossing the barrier.

Brian Vastag.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20725015     DOI： 10.1038/466916a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

Review 1.  The GDNF family: signalling, biological functions and therapeutic value.

Authors:  Matti S Airaksinen; Mart Saarma
Journal:  Nat Rev Neurosci       Date:  2002-05       Impact factor: 34.870

2.  Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.

Authors:  Steven S Gill; Nikunj K Patel; Gary R Hotton; Karen O'Sullivan; Renée McCarter; Martin Bunnage; David J Brooks; Clive N Svendsen; Peter Heywood
Journal:  Nat Med       Date:  2003-03-31       Impact factor: 53.440

3.  Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate.

Authors:  W M Pardridge; Y S Kang; J L Buciak; J Yang
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

4.  Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.

Authors:  William M Pardridge; Ruben J Boado
Journal:  Pharm Res       Date:  2009-07-17       Impact factor: 4.200

5.  Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain.

Authors:  Seth Love; Puneet Plaha; Nikunj K Patel; Gary R Hotton; David J Brooks; Steven S Gill
Journal:  Nat Med       Date:  2005-07       Impact factor: 53.440
  5 in total
  5 in total

Review 1.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

Review 2.  A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

Authors:  Shams Tabrez; Nasimudeen R Jabir; Shazi Shakil; Nigel H Greig; Qamre Alam; Adel M Abuzenadah; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

Review 3.  Engaging neuroscience to advance translational research in brain barrier biology.

Authors:  Edward A Neuwelt; Björn Bauer; Christoph Fahlke; Gert Fricker; Constantino Iadecola; Damir Janigro; Luc Leybaert; Zoltán Molnár; Martha E O'Donnell; John T Povlishock; Norman R Saunders; Frank Sharp; Danica Stanimirovic; Ryan J Watts; Lester R Drewes
Journal:  Nat Rev Neurosci       Date:  2011-03       Impact factor: 34.870

4.  Incomplete copolymer degradation of in situ chemotherapy.

Authors:  Pierre Bourdillon; Tanguy Boissenot; Lauriane Goldwirt; Julien Nicolas; Caroline Apra; Alexandre Carpentier
Journal:  J Mater Sci Mater Med       Date:  2018-02-17       Impact factor: 3.896

5.  A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys.

Authors:  Sachiko Ohshima-Hosoyama; Heather A Simmons; Nichole Goecks; Valerie Joers; Christine R Swanson; Viktoriya Bondarenko; Rebecca Velotta; Kevin Brunner; Laura D Wood; Ralph H Hruban; Marina E Emborg
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.